ArticleThe Journal of allergy and clinical immunology2017
Abnormal CD161
Article in The Journal of allergy and clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- A guide to cell-type-specific Cre mouse models in atherosclerosis: from background strains to future directions.Frontiers in cardiovascular medicine · 2026Review
- RORγt Mediates Angiotensin II-Induced Pressor Responses, Microglia Activation, and Neuroinflammation by Disrupting the Blood-Brain Barrier in Rats.Journal of the American Heart Association · 2025Article
- Immunobiology roles of the human CD161 receptor in T cells.Frontiers in immunology · 2025Review
- Improvement of the Immunity System Through Sports: Novel Regulatory Mechanisms for Hypertension.Reviews in cardiovascular medicine · 2024Review
- Immune and inflammatory mechanisms in hypertension.Nature reviews. Cardiology · 2024Review
- Brain nuclear receptors and cardiovascular function.Cell & bioscience · 2023Review
- Mass Cytometry Reveals the Imbalanced Immune State in the Peripheral Blood of Patients with Essential Hypertension.Cardiovascular therapeutics · 2023Article
- Deeper insight into the role of IL-17 in the relationship beween hypertension and intestinal physiology.Journal of inflammation (London, England) · 2022Review
- Update on Immune Mechanisms in Hypertension.American journal of hypertension · 2022Review
- Four evolving concepts in molecular and clinical autonomic research.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2021Article
- Altering Early Life Gut Microbiota Has Long-Term Effect on Immune System and Hypertension in Spontaneously Hypertensive Rats.Frontiers in physiology · 2021Article
- Pro-Inflammatory Signature in Decidua of Recurrent Pregnancy Loss Regardless of Embryonic Chromosomal Abnormalities.Frontiers in immunology · 2021Article
- Nox1/4 inhibition exacerbates age dependent perivascular inflammation and fibrosis in a model of spontaneous hypertension.Pharmacological research · 2020Article
- Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?International journal of hypertension · 2019Review
- Cytotoxic activity of Kingella kingae RtxA toxin depends on post-translational acylation of lysine residues and cholesterol binding.Emerging microbes & infections · 2018Article
- Autonomic regulation of the immune system in cardiovascular diseases.Advances in physiology education · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundHypertension is considered an immunologic disorder. However, the role of the IL-17 family in genetic hypertension in the spontaneously hypertensive rat (SHR) has not been investigated.
objectiveWe tested the hypothesis that enhanced T
methodsWe measured expression of the CD161 surface marker on splenocytes in SHRs and normotensive control Wistar-Kyoto (WKY) rats from birth to adulthood. We compared expression of IL-17A and IL-17F in splenic cells under different conditions. We then determined the functional effect of these cytokines on vascular reactivity. Finally, we tested whether pharmacologic inhibition of RORγt can attenuate hypertension in SHRs.
resultsSHRs exhibited an abnormally large population of CD161
conclusionsSHRs have a markedly enhanced potential for RORγt-driven expression of proinflammatory and prohypertensive IL-17F in response to innate immune activation. Increased RORγt and IL-17F levels contribute to SHR hypertension and might be therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.